Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 - MyChesCo
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) recently announced updated clinical data from Imagine-1, a Phase 1/2 study of PBGM01, a gene therapy for GM1 gangliosidosis (GM1), presented Friday …
MyChesCo
